Investors cheering China's market expansion should be careful what they wish for

Equities Emerging markets febrero 2018

3 minute read

A new pilot scheme could give investors greater access to China’s vast equity market. But the project may also affect the performance of existing Hong Kong-listed shares, says Will Ballard.

For equity investors clamouring for more access to the Chinese market, 2018 opened with some good news. The China Securities Regulatory Commission (CSRC) has confirmed a pilot scheme under which three mainland companies will be allowed to release some of their non-tradeable H shares into circulation on the Hong Kong Stock Exchange.1

While the announcement was made with little fanfare, it could have some major implications for the Chinese equity market. If the scheme is successful it could be rolled out to other mainland firms listed in Hong Kong, many of which currently have a significant portion of their share capital locked up due to strict regulation. According to UBS research, 154 Chinese companies are sitting on non-tradeable H shares worth a collective HK$2.6 trillion ($332 billion).

Time will tell whether the CSRC will sanction the free release of all of these H shares given the regulator’s traditional reluctance to relax control of cross-border capital flows. Nevertheless, the scheme looks promising. Freeing up mainland companies’ share capital should boost liquidity and bring about a greater alignment between controlling parties and public investors, among other benefits. But any expansion of the Chinese equity market could also affect the performance of shares that are already listed.

China’s market reforms

Before considering these potential consequences, it’s worth exploring the thinking behind the CSRC pilot scheme, which should be understood in the context of China’s wider market reform efforts. In the absence of mature bond and equity markets, Chinese companies rely heavily on bank loans and the authorities are keen to open up different sources of funding.

This was the motivation behind the government’s attempts to expand and liberalise the country’s equity market in 2015, although it will be hopeful of a better outcome this time around. The 2015 process was badly handled, and the ensuing sell-off sent shockwaves through global markets.

The CSRC pilot scheme is a more modest initiative but the objective is the same as it was three years ago: to give Chinese firms more freedom to tap equity and bond markets for longer-term, more-sustainable funding.

As President Xi Jinping indicated during the 19th Party Plenum in October 2017, the government is also keen to reform China’s state-owned enterprises (SOEs). Xi’s administration recognises the preponderance of unwieldy and uncompetitive SOEs is hampering the transfer of capital and resources to more productive sectors and ultimately undermining economic stability. Enabling SOEs to issue more H-shares could help by broadening these companies’ ownership bases and encouraging a greater focus on investment returns and efficiency.

Expanding the market

Yet while the CSRC pilot scheme could bring some benefits for investors and policymakers, it may also impact performance. To understand why, you need to look at the dynamics of market expansion.

Equity markets can grow in one of two ways. First, the constituent companies can rise in value, lifting the market capitalisation of the whole index. This is what has occurred during the bull market in US equities over the last few years. So-called ‘de-equitisation’ played a role; due to the widespread practice of equity buy-backs, de-listings and take-overs, the number of free-float adjusted shares outstanding on the MSCI North America Index has declined to its lowest level since 2010. As the number of listed shares declines, the price of those that remain tends to go up.

The other way for a market to grow is through the issuance of new shares. This is more common in fast-growing emerging economies. Take Turkey, for example. The Turkish market is likely to see about $4-4.5 billion in equity issuance this year, comprising both initial public offerings (IPOs) and new issuance from already-listed companies, many of which are looking to convert euro-denominated debt into equity in order to refinance it.

The problem is that only $3-3.5 billion of new investor capital entered the Turkish equity market last year. Unless that figure rises sharply in 2018, investors will likely need to sell stocks they already own to buy the new issuance, which could impact share prices and lead to poor relative performance across the market.

Headwinds to performance

This is the risk investors in China should be mindful of as the CSRC pilot scheme progresses. The share count of the Chinese market is already increasing at a meteoric rate (see figure 1), feeding a constant demand for liquidity simply to support the overall index level.

Figure 1. Share count in MSCI North America vs MSCI China

Figure 2 shows how the share count on the Hang Seng China Enterprises Index (HSEI), which tracks mainland companies listed in Hong Kong, has increased over the last decade. The dotted line indicates the extent to which the share count could rise still further, were the full amount of H-shares to be unlocked.

Figure 2. HSCEI share count and index performance

In periods of rapid market appreciation, a 10-15 per cent increase in the total number of shares outstanding would probably not have a drastic effect on overall market price appreciation, and a drastic sell-off seems unlikely.  However, should 2018 prove to be a weaker year for the Chinese equity market than 2017, this type of additional supply could be an additional headwind to performance.

All this considered, market participants keen for more H-shares to invest in should be wary of how their existing portfolio might be affected should the floodgates open in Hong Kong.

Important Information

Except where stated as otherwise, the source of all information is Aviva Investors Global Services Limited (Aviva Investors) as at February 19 2018. Unless stated otherwise any view sand opinions are those of Aviva Investors. They should not be viewed as indicating any guarantee of return from an investment managed by Aviva Investors nor as advice of any nature. Information contained herein has been obtained from sources believed to be reliable, but has not been independently verified by Aviva Investors and is not guaranteed to be accurate. Past performance is not a guide to the future. The value of an investment and any income from it may go down as well as up and the investor may not get back the original amount invested. Nothing in this document, including any references to specific securities, assets classes and financial markets is intended to or should be construed as advice or recommendations of any nature. This document is not a recommendation to sell or purchase any investment.

In the UK & Europe this document has been prepared and issued by Aviva Investors Global Services Limited, registered in England No.1151805. Registered Office: St. Helen’s, 1 Undershaft, London, EC3P 3DQ. Authorised and regulated in the UK by the Financial Conduct Authority. Contact us at Aviva Investors Global Services Limited, St. Helen’s, 1 Undershaft, London, EC3P 3DQ. Telephone calls to Aviva Investors may be recorded for training or monitoring purposes. In Singapore, this document is being circulated by way of an arrangement with Aviva Investors Asia Pte. Limited for distribution to institutional investors only. Please note that Aviva Investors Asia Pte. Limited does not provide any independent research or analysis in the substance or preparation of this document. Recipients of this document are to contact Aviva Investors Asia Pte. Limited in respect of any matters arising from, or in connection with, this document.  Aviva Investors Asia Pte.  Limited, a company incorporated under the laws of Singapore with registration number200813519W, holds a valid Capital Markets Services Licence to carry out fund management activities issued under the Securities and Futures Act (Singapore Statute Cap. 289) and Asian Exempt Financial Adviser for the purposes of the Financial Advisers Act (Singapore Statute Cap.110). Registered Office: 1Raffles Quay, #27-13 South Tower, Singapore 048583.In Australia, this document is being circulated by way of an arrangement with Aviva Investors Pacific Pty Ltd for distribution to wholesale investors only. Please note that Aviva Investors Pacific Pty Ltd does not provide any independent research or analysis in the substance or preparation of this document. Recipients of this document are to contact Aviva Investors Pacific Pty Ltd in respect of any matters arising from, or in connection with, this document. Aviva Investors Pacific Pty Ltd, a company incorporated under the laws of Australia with Australian Business No. 87 153 200 278 and Australian Company No. 153 200 278, holds an Australian Financial Services License (AFSL 411458) issued by the Australian Securities and Investments Commission. Business Address: Level 30, Collins Place, 35 Collins Street, Melbourne, Vic 3000

The name “Aviva Investors” as used in this presentation refers to the global organization of affiliated asset management businesses operating under the Aviva Investors name. Each Aviva investors’ affiliate is a subsidiary of Aviva plc, a publicly- traded multi-national financial services company headquartered in the United Kingdom. Aviva Investors Canada, Inc. (“AIC”) is located in Toronto and is registered with the Ontario Securities Commission (“OSC”) as a Portfolio Manager, an Exempt Market Dealer, and a Commodity Trading Manager. Aviva Investors Americas LLC is a federally registered investment advisor with the U.S. Securities and Exchange Commission. Aviva Investors Americas is also a commodity trading advisor (“CTA”) and commodity pool operator (“CPO”) registered with the Commodity Futures Trading Commission (“CFTC”), and is a member of the National Futures Association (“NFA”).  AIA’s Form ADV Part 2A, which provides background information about the firm and its business practices, is available upon written request to: Compliance Department, 225 West Wacker Drive, Suite 2250, Chicago, IL 60606

RA18/0225/01012019